Funds to be used to drive transformative strategic growth initiatives
Tokyo, Japan and London, UK, 16 July 2020 – Sosei Group Corporation (“the Company”; TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen denominated convertible bonds due 2025 that has raised a total of approximately $200 million. Further details of the International Offering can be found in the Company announcements made on 30 June 2020.
The Company intends to use the net proceeds of the International Offering as follows:
The majority of funds will be used…
Industry programme created to solve the business challenges that keep life sciences leaders and innovators up at night.
Deloitte has launched the Life Sciences Catalyst in Cambridge, a collaborative platform enabling organisations in the biotech, medtech, pharmaceutical and technology sectors, as well as prospective investors, to come together to tackle the biggest challenges facing their industries.
The Life Sciences Catalyst will facilitate connections between people, businesses and investors to support companies with their growth, regardless of their evolutionary stage. It has a physical…
The research use only kit can be used as a simple alternative to RT-qPCR for SARS-CoV-2 analysis
IPSWICH, MA (July 6, 2020): New England Biolabs® (NEB®) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA. The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes.
Read Full Press Release Here > https://www.neb.com/about-neb/news-and-press-releases/sars-cov-2-rapid-…
- Muscular Dystrophy UK (MDUK) supports high quality research that drives rapid access to emerging therapies for people with muscle-wasting conditions.
- Facioscapulohumeral muscular dystrophy (FSHD) is a rare muscle-wasting disease affecting an estimated 3-5 in every 100,000 people worldwide.
- This partnership will combine Healx’s AI-driven drug discovery expertise with MDUK’s patient insight to identify novel therapeutic options for FSHD.
Cambridge UK – 15 July 2020 – Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease…
The BioChemGRAPH collaboration brings together key chemical and biochemical datasets, to give researchers deeper insights than ever before.
A collaboration announced today will see the integration of key structural, functional, and biochemical data across both small molecules and macromolecules. This will allow researchers to quickly access relevant information from trusted but disparate datasets, advancing work in fields such as target validation, drug development, drug repurposing and cross-reactivity.
The Aim
The BioChemGRAPH project will create an easily accessible web platform to bring…
Cambridge, United Kingdom – 15 July 2020 - Congenica, a digital health company enabling rapid analysis of complex genomic data, has launched an update for its clinical decision support platform that will provide automated classification, evidence and reporting of recurrent ‘known’ variants that customers observe in their rare disease cases, significantly saving time while maximizing diagnostic yield and laboratory throughput.
The key to realizing the potential of precision medicine relies on accurate and efficient diagnosis. However, even less complex cases can take experts 11-12 hours using…
Eastern AHSN (Academic Health Science Network) has published its latest impact review (for the period April 2019 to 31 March 2020) highlighting how they turned great ideas into positive health impact last year, told largely in the words of the people they worked with.
The review covers the breadth and depth of their collaborations to deliver some major successes in terms of patient and investment impact and includes an overview of their role supporting NHS partners’ response to the COVID-19 crisis.
Highlights of the year included helping reduce the number of avoidable strokes in the region,…
San Diego, California and Saffron Walden, UK, 14th July 2020 / Sciad Newswire / Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities to accelerate drug development.
Invivoscribe’s therapeutics division also announced today that the company has in-licensed technology involving a preclinical molecule and associated small molecules from…
Cambridge, UK, 7th July 2020: Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB). Dr. Mayr will initially join the Board of Directors as an observer, providing valuable insights into the development and manufacture of ex vivo cell therapies and in vivo reprogramming therapies and advising on the Company’s therapeutic program selections, before assuming full…
A Spanish SME, in collaboration with a local University, has been developing an advanced drug delivery system which allows to increase the therapeutic efficacy of chemotherapeutics against Non-Small Cell Lung Cancer (NSCLC). The goal of this Eurostars proposal is to obtain a full-characterized antitumoral product ready to be tested in clinical trials. They are looking for a partner to carry out the preclinical regulatory trials.
Cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer (…